NeuroOne Medical Technologies Corporation
NMTC · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | 0.07 | -0.43 | 0.08 |
| FCF Yield | -8.18% | -42.02% | -82.25% | -28.83% |
| EV / EBITDA | -9.76 | -2.14 | -0.94 | -1.92 |
| Quality | ||||
| ROIC | -49.11% | -368.88% | -185.82% | -102.28% |
| Gross Margin | 67.30% | 31.27% | 23.38% | -41.36% |
| Cash Conversion Ratio | 0.79 | 0.89 | 1.09 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | 83.67% | 172.22% | 122.13% | 555,132.70% |
| Free Cash Flow Growth | 73.78% | 16.12% | -70.26% | 10.09% |
| Safety | ||||
| Net Debt / EBITDA | 2.09 | 0.10 | 0.44 | 0.80 |
| Interest Coverage | 0.00 | -51.91 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.78 | 0.90 | 0.87 | 0.34 |
| Cash Conversion Cycle | 150.39 | 265.65 | 254.14 | -265.71 |